Key Highlights
- The third-quarter net loss widened to USD 7,382,080 from USD 4,801,149, equal to USD 0.17 a share against USD 0.13 a year earlier.
- Cash fell from USD 1,384,302 at December 31, 2025 to just USD 92,458 by September 30, 2026, while current liabilities sat near USD 15.6 million.
- Research and development spending climbed 66.2% to roughly USD 6.9 million after five patients were dosed in STARLIGHT-1, compared with three in the prior-year period.
- Nasdaq raised two issues: a closing bid below USD 1.00, due for cure by February 16, 2027, and a listed securities value under USD 35.0 million, with a March 1, 2027 date.
Trial Dosing Pushes Up the Quarterly Loss
Estrella Immunopharma (NASDAQ:ESLA) remains a clinical-stage biotech working on ARTEMIS T-cell therapies, with its lead candidate EB103 in the Phase I/II STARLIGHT-1 study, and it generates no product revenue. For the quarter ended September 30, 2026, R&D costs reached roughly USD 6.9 million, an increase of USD 2.7 million, since five patients received doses under the statement of work with Eureka Therapeutics, versus three a year earlier. G&A held near USD 0.6 million. A derivative Fair Value gain of about USD 0.1 million softened the USD 7.4 million net loss. On a per-share basis the loss was USD 0.17, up from USD 0.13 in the prior-year quarter, and the company has yet to start revenue-generating activity since its formation on March 30, 2022.
Nine-Month Loss Narrows, Yet Cash Runs Very Low
Across nine months the net loss came to USD 11,980,483, compared with USD 12,450,338, while R&D eased 5.1% to about USD 9.7 million because a second-site activation fee did not recur. The Balance Sheet is much weaker: cash of USD 92,458 faces current liabilities near USD 15.6 million, including about USD 15.1 million of accrued milestone obligations to Eureka. Operating cash outflow reached roughly USD 8.7 million over nine months, and the accumulated Deficit stands near USD 49.0 million.
Going-Concern Warning, Deferred Pay and Listing Notices
Estrella Immunopharma (NASDAQ:ESLA) management reports substantial doubt about the company's ability to continue as a going concern, adding that funding depends on Debt or Equity raises that might not be obtainable. The January 2026 registered direct offering and private Placement produced about USD 8.0 million gross. Executives have deferred salaries since May 22, 2026, and on November 11, 2026 deferral agreements were executed with the former chief executive, the chief financial officer and the new chief executive, Cynthia Pussinen. Nasdaq separately highlighted a closing bid under USD 1.00 and listed securities valued below USD 35.0 million.
Where Things Stand
Not on current evidence: Estrella Immunopharma (NASDAQ:ESLA) has just USD 92,458 in the bank and roughly USD 15.6 million owed in near-term obligations, alongside a going-concern warning. Operations therefore hinge on new financing that management aims to secure, although it gives no guarantee. The USD 7.4 million quarterly loss stemmed from heavier dosing costs, since the company has no Revenue to offset it. Key dates to monitor are any financing announcements, the Nasdaq compliance deadlines of February 16, 2027 and March 1, 2027, further STARLIGHT-1 milestone payments to Eureka and whether the deferred pay, which totalled USD 198,077 at September 30, 2026, is repaid once funds arrive.






Please wait processing your request...